

TRADEMARK ASSIGNMENT COVER SHEET

Electronic Version v1.1
Stylesheet Version v1.2

ETAS ID: TM344644

SUBMISSION TYPE:	NEW ASSIGNMENT		
NATURE OF CONVEYANCE:	ASSIGNMENT OF THE ENTIRE INTEREST AND THE GOODWILL		
CONVEYING PARTY DATA			
Name	Formerly	Execution Date	Entity Type
King Pharmaceuticals Research and Development, Inc.		04/09/2015	CORPORATION: DELAWARE
RECEIVING PARTY DATA			
Name:	Pain Therapeutics, Inc.		
Street Address:	7801 N Capital of Texas Highway		
Internal Address:	Suite 260		
City:	Austin		
State/Country:	TEXAS		
Postal Code:	78701		
Entity Type:	CORPORATION: DELAWARE		
PROPERTY NUMBERS Total: 1			
Property Type	Number	Word Mark	
Serial Number:	86136868	REMOXY	
CORRESPONDENCE DATA			
Fax Number:	3128278185		
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>			
Phone:	312-807-4350		
Email:	chicago.trademarks@klgates.com, sana.hakim@klgates.com		
Correspondent Name:	Sana Hakim c/o K&L Gates LLP		
Address Line 1:	P.O. Box 1135		
Address Line 4:	Chicago, ILLINOIS 60690-1135		
NAME OF SUBMITTER:	Sana Hakim		
SIGNATURE:	/sh/		
DATE SIGNED:	06/15/2015		
Total Attachments: 2			
source=1REMOXYtradeMarkAssignment#page1.tif			
source=1REMOXYtradeMarkAssignment#page2.tif			

CH \$40.00 86136868

TRADEMARK ASSIGNMENT

WHEREAS, King Pharmaceuticals Research and Development, Inc., a Corporation organized and existing under the laws of Delaware, with a place of business at 4000 Centregreen Way, Suite 300, Cary, North Carolina 27513, is the owner of the following:

- 1) The trademark REMOXY registered in the CTM under Registration Number CTM007009673;
- 2) The trademark REMOXY registered in Japan under Registration Number 2008049055;
- 3) The Trademark REMOXY applied for in the U.S. under Application Number 86136868;
- 4) The trademark REMOXY applied for in Canada under Application Number 1682063
- 5) The Trademark REMOXY and Design registered in the CTM under Registration Number CTM008288491;
- 6) The Trademark REMOXY and Design registered in Japan under Registration Number 2009034591;

And, Whereas Pfizer Inc., a Corporation organized and existing under the laws of Delaware, with a place of business at 235 East 42nd Street, New York, New York 10017, is the owner of the following:

- 7) The Trademark REMOXY registered in Norway under Registration Number 201101704;
- 8) The Trademark REMOXY registered in Switzerland under Registration Number 51700/2011;


Hereinafter the "Assignors" and the "Trademarks".

WHEREAS, Pain Therapeutics, Inc. ("Assignee"), a Corporation organized and existing under the laws of Delaware, with a place of business at 7801 N. Capital of Texas Hwy Suite 260, Austin, Texas 78731, desires to acquire the rights and goodwill associated with the Mark as owned by Assignor.


NOW THEREFORE, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, Assignors hereby transfer, release and assign to Assignee, effective as of the date signed below, all right, title and interest in and to the Trademarks, together with (1) the goodwill associated therewith, (2) Registration/Application Number for the Trademarks, and (3) all common law rights in the Trademarks, for its own use and behalf and for the use and behalf of its successors, assigns and other legal representatives. Assignee avers that they will take all necessary steps for and pay all costs relating to the recordal of this assignment with any relevant Trademark Offices.

This Trademark Assignment may be executed in counterparts, each of which shall be deemed an original, but all of which together shall be deemed to be one and the same agreement. A signed copy of this Trademark Assignment delivered by facsimile, email or other means of electronic transmission shall be deemed to have the same legal effect as delivery of an original signed copy of this Trademark Assignment.


Signed: Pfizer Inc.


By: Heather McDonald
Assistant General Counsel - IP
Date: April 9, 2015

Signed: King Pharmaceuticals Research and Development Inc.


By: Richard A. Friedman
Attorney-in-Fact
Date: April 9, 2015

Signed: Pain Therapeutics Inc.


By: RAMI BARLIER
Date: 04/09/15